A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamic Effect of MK-5160 in Subjects With Type 1 and Type 2 Diabetes Mellitus
Phase of Trial: Phase I
Latest Information Update: 05 May 2017
At a glance
- Drugs MK 5160 (Primary) ; Glucose; Insulin glargine
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Acronyms MK-5160-002
- Sponsors Merck Sharp & Dohme
- 28 Apr 2017 Planned End Date changed from 6 Oct 2017 to 30 Nov 2017.
- 28 Apr 2017 Planned primary completion date changed from 6 Oct 2017 to 30 Nov 2017.
- 28 Apr 2017 Status changed from not yet recruiting to recruiting.